100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R41DK122897
Award Date
9/17/19
Completion Date
8/31/21
Dollars Obligated
$225K
Overview
Activity
3
Transactions
3
Subawards
Similar Awards
Federal Agency
National Institute of Diabetes and Digestive and Kidney Diseases
Awardee
Abri Science, LLC (CMPRHZJGJ3H1)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Update #1
Update #2
ORAL ENZYMATIC MANAGEMENT OF PHENYLKETONURIA
Posted 9/16/19
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
ORAL ENZYMATIC MANAGEMENT OF PHENYLKETONURIA - PHENYLKETONURIA (PKU) IS A GENETIC DISORDER OF METABOLISM CHARACTERIZED BY A PATHOLOGICAL ELEVATION OF PHENYLALANINE (PHE) IN THE BODY STEMMING FROM A DYSFUNCTIONAL PHENYLALANINE HYDROXYLASE ENZYME (PAH). THE RESULTING HIGH CONCENTRATIONS OF PHE (5-10X) CAN RESULT IN SEVERE INTELLECTUAL DISABILITY, BEHAVIORAL PROBLEMS, AND NEUROLOGICAL DEFICITS (E.G. SEIZURES). STRICT CONTROL OF DIETARY PHE IS THE PRIMARY TREATMENT FOR PKU CURRENT GUIDELINES REQUIRE DIET THERAPY TO BE CONTINUED FOR LIFE, WHICH MARKEDLY EXACERBATES THE PROBLEM OF NON-COMPLIANCE, ESPECIALLY IN OLDER CHILDREN AND ADULTS. AN ALTERNATIVE TREATMENT FOR PKU INVOLVES THE "REPLACEMENT" OF THE ENDOGENOUS PAH WITH A DIFFERENT PHE METABOLIZING ENZYME SUCH AS PHENYLALANINE AMMONIA LYASE (PAL). ORALLY ADMINISTERED PAL REDUCED PLASMA PHE LEVELS, BUT THIS EFFECT WAS TRANSIENT AS THE DESTRUCTION OF PAL BY HARSH ENVIRONMENT OF THE GASTROINTESTINAL TRACT (G.I.T) NECESSITATED HUGE DOSES OF THE ENZYME. WE HAVE DESIGNED A NOVEL TECHNOLOGY TO REDUCE DIETARY PHE LEVELS IN THE G.I.T. BY ORAL ADMINISTRATION OF MICROENCAPSULATED PAL. PRELIMINARY STUDIES HAVE DEMONSTRATED THAT WE CAN SUCCESSFULLY ENCAPSULATE PAL (PALE) IN ETHYL CELLULOSE USING A PATENTED EMULSION-DISPERSION TECHNIQUE. HOWEVER, PALE EXHIBITS ~30% OF THE ACTIVITY OF UNENCAPSULATED ENZYME (PALU) IN SOLUTION LIMITING ITS IMPLEMENTATION IN ITS CURRENT FORM. THE GOAL OF THIS PROPOSAL IS TO OPTIMIZE THE FORMULATION PARAMETERS TO ENCAPSULATE PAL AND CHARACTERIZE ITS PROPERTIES IN VITRO ENABLING FUTURE DEVELOPMENT EFFORTS.
$0
2/28/22
Not listed
ORAL ENZYMATIC MANAGEMENT OF PHENYLKETONURIA - PHENYLKETONURIA (PKU) IS A GENETIC DISORDER OF METABOLISM CHARACTERIZED BY A PATHOLOGICAL ELEVATION OF PHENYLALANINE (PHE) IN THE BODY STEMMING FROM A DYSFUNCTIONAL PHENYLALANINE HYDROXYLASE ENZYME (PAH). THE RESULTING HIGH CONCENTRATIONS OF PHE (5-10X) CAN RESULT IN SEVERE INTELLECTUAL DISABILITY, BEHAVIORAL PROBLEMS, AND NEUROLOGICAL DEFICITS (E.G. SEIZURES). STRICT CONTROL OF DIETARY PHE IS THE PRIMARY TREATMENT FOR PKU CURRENT GUIDELINES REQUIRE DIET THERAPY TO BE CONTINUED FOR LIFE, WHICH MARKEDLY EXACERBATES THE PROBLEM OF NON-COMPLIANCE, ESPECIALLY IN OLDER CHILDREN AND ADULTS. AN ALTERNATIVE TREATMENT FOR PKU INVOLVES THE "REPLACEMENT" OF THE ENDOGENOUS PAH WITH A DIFFERENT PHE METABOLIZING ENZYME SUCH AS PHENYLALANINE AMMONIA LYASE (PAL). ORALLY ADMINISTERED PAL REDUCED PLASMA PHE LEVELS, BUT THIS EFFECT WAS TRANSIENT AS THE DESTRUCTION OF PAL BY HARSH ENVIRONMENT OF THE GASTROINTESTINAL TRACT (G.I.T) NECESSITATED HUGE DOSES OF THE ENZYME. WE HAVE DESIGNED A NOVEL TECHNOLOGY TO REDUCE DIETARY PHE LEVELS IN THE G.I.T. BY ORAL ADMINISTRATION OF MICROENCAPSULATED PAL. PRELIMINARY STUDIES HAVE DEMONSTRATED THAT WE CAN SUCCESSFULLY ENCAPSULATE PAL (PALE) IN ETHYL CELLULOSE USING A PATENTED EMULSION-DISPERSION TECHNIQUE. HOWEVER, PALE EXHIBITS ~30% OF THE ACTIVITY OF UNENCAPSULATED ENZYME (PALU) IN SOLUTION LIMITING ITS IMPLEMENTATION IN ITS CURRENT FORM. THE GOAL OF THIS PROPOSAL IS TO OPTIMIZE THE FORMULATION PARAMETERS TO ENCAPSULATE PAL AND CHARACTERIZE ITS PROPERTIES IN VITRO ENABLING FUTURE DEVELOPMENT EFFORTS.
$0
2/28/22
Not listed
ORAL ENZYMATIC MANAGEMENT OF PHENYLKETONURIA
$225.0k
9/16/19